McKinsey’s recent analysis reveals renewed optimism and a sharper strategic outlook for dealmaking in the life sciences industry in 2026. After the volatility of the past few years, shaped by geopolitical and macroeconomic tension and regulatory uncertainty, leaders’ confidence in M&A is returning. The change is being driven by strong balance sheets and increasing urgency to augment pipelines. The market appears to be rebounding: Total deal value in the life sciences industry reached $372 billion in 2025. This increase of 47 percent year over year signals renewed confidence despite continued headwinds from elevated interest rates and evolving global trade policies.
Read the full article: Life Sciences: Dealmaking Gains Momentum as Strategic Pressures Intensify //
Source: https://www.mckinsey.com/capabilities/m-and-a/our-insights/life-sciences-dealmaking-gains-momentum-as-strategic-pressures-intensify